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The present work investigates the occurrence and sig-
nificance of aberrant DNA methylation patterns during
early stages of atherosclerosis. To this end, we asked
whether the genetically atherosclerosis-prone APOE-
null mice show any changes in DNA methylation pat-
terns before the appearance of histologically detectable
vascular lesion. We exploited a combination of various
techniques: DNA fingerprinting, in vitro methyl-accept-
ing assay, 5-methylcytosine quantitation, histone post-
translational modification analysis, Southern blotting,
and PCR. Our results show that alterations in DNA
methylation profiles, including both hyper- and hypo-
methylation, were present in aortas and PBMC of
4-week-old mutant mice with no detectable atheroscle-
rotic lesion. Sequencing and expression analysis of 60
leukocytic polymorphisms revealed that epigenetic
changes involve transcribed genic sequences, as well as
repeated interspersed elements. Furthermore, we
showed for the first time that atherogenic lipoproteins
promote global DNA hypermethylation in a human
monocyte cell line. Taken together, our results unequiv-
ocally show that alterations in DNA methylation profiles
are early markers of atherosclerosis in a mouse model
and may play a causative role in atherogenesis.
Atherosclerosis and its complications are a major cause of
death and disability in the developed world. The disease is
characterized by infiltration of lipid particles in the arterial
wall, accompanied by the recruitment of inflammatory and
immune cells, migration and proliferation of smooth muscle
cells (SMC),1 and synthesis of extracellular matrix. These pro-
cesses eventually result in the gradual development of an ele-
vated lipid-rich, fibrocellular lesion (1).
In mammals, DNA methyltransferases use S-adenosyl me-
thionine (SAM) as a methyl group donor to methylate the
carbon in position 5 of cytosine residues in a CpG dinucleotide
(CG) context (2). DNA methylation regulates fundamental bi-
ological phenomena such as gene expression, genome stability,
mutation rate, genomic imprinting, and X chromosome inactiva-
tion (3–6). Both global and gene-specific alterations in DNA
methylation are associated with abnormal phenotypes in disease
(7, 8). For example, cancer cells show global genomic hypometh-
ylation and dense hypermethylation of CpG islands, which are
normally unmethylated (9). The identification of cancer type- and
stage-specific changes in DNA methylation has justified hopes for
novel diagnostic and therapeutic avenues (10).
Two general observations suggest that alterations in DNA
methylation patterns are involved in atherogenesis (11–13).
First, global hypomethylation and dense hypermethylation of
certain CpG islands are associated with aging, a major risk
factor for atherosclerosis (14). Second, hyperhomocysteinemia
and the subsequent decreased production or bioavailability of
SAM is associated with an increased risk of cardiovascular
disease (15). Accordingly, mice with genetically reduced levels
of methylenetetrahydrofolate reductase, a key enzyme in the
pathway generating SAM, show hyperhomocysteinemia, DNA
hypomethylation, and aortic lipid infiltrations (16). Further-
more, a global DNA hypomethylation has been observed in
vascular lesions and leukocytes of atherosclerosis patients and
proliferating SMC in animal models (17–19).
One unresolved issue is whether DNA methylation patterns
are altered at early stages of atherosclerosis and are associated
with susceptibility to the disease. Answers to these questions
may have important implications for prevention and therapy of
atherosclerosis. We therefore asked whether changes in DNA
methylation patterns occur prior to the appearance of any
vascular lesions in PBMC and aorta of mice lacking APOE,
compared with matched WT animals (20). Moreover, in an
attempt to provide a mechanism for the changes in DNA meth-
ylation patterns observed in vivo, we asked whether athero-
genic lipoprotein profiles could affect DNA methylation and
histone post-translational modifications in the human mono-
cyte-macrophage cell line THP-1 (21). The present study is the
first analysis of DNA methylation at early stages of atheroscle-
rosis and the first description of genomic DNA sequences un-
dergoing epigenetic changes in a mouse model. The implica-
tions of our findings for understanding human atherosclerosis
are discussed.
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EXPERIMENTAL PROCEDURES
Animal Work and Tissue Manipulation—All procedures used in this
study were approved by the local ethical committee (Malmö/Lunds
Djurförsöksetiska Nämnd, license M89-01). Apoe nullizygous mice
(Apoe/) of the strain created in the laboratory of N. Maeda (20) were
purchased from M&B (Ry, Denmark) and were at the 10th generation
of breeding on to the C57BL/6 genetic background. Four-week- and
6-month-old Apoe/ or C57BL/6 control mice were sacrificed and dis-
sected following overnight fasting. Dissections were performed accord-
ing to anatomic maps of the mouse (22). The aortic tissue used in this
study included the thoracic portion from the middle of the aortic arch
and the abdominal portion to the iliac bifurcation. The initial portion of
the ascending aorta was used to assess the presence of fatty lesions as
described (23). PBMC were isolated by Ficoll-Paque PLUS gradient
according to the instructions from the manufacturer (Amersham Bio-
sciences, Little Chalfont, United Kingdom (UK)). Skeletal muscle tissue
was dissected from the pelvic limb. Genomic DNA or total RNA were
extracted by using the DNeasy or RNeasy system (Qiagen, Valencia,
CA), respectively, according to manufacturer instructions. The levels of
plasma cholesterol and triglycerides were measured as described (23).
Methylation-sensitive Amplified Polymorphism (MSAP) Analysis—
DNA methylation profiles were analyzed by the MSAP as reported (24)
with the following modifications.
Restriction Digest of Genomic DNA and Attachment of Adaptors—All
enzymes used in the MSAP protocol were provided by New England
Biolabs (Hertfordshire, UK). Five hundred nanograms of genomic DNA
were digested for 1 h with 20 units of HpaII and EcoRI using NEB buffer
1 in a 30-l reaction volume. Subsequently, the restriction digest and
ligation reactions were carried out simultaneously for an additional 3 h in
a final volume of 40 l. The restriction-ligation mix contained 10 units of
HpaII, 10 units of EcoRI, 10 units of T4 DNA ligase, 5 pmol EcoRI
adaptor, 50 pmol HpaII adaptor and 1 mM ATP. The enzymes were
inactivated for 15 min at 65 °C, and a second digest was performed for 1 h
with 5 units of HpaII and EcoRI, again followed by heat inactivation. The
adaptor sequences were as follows: EcoRI adaptor, 5-CTCGTAGACT-
GCGTACC-3 and 5-AATTGGTACGCAGTCTAC-3; HpaII adaptor, 5-
GATCATGAGTCCTGCT-3 and 5-CGAGCAGGACTCATGA-3.
Preamplification—The preamplification reaction was performed
with primers complementary to the core of the adaptor sequences and
the target sequence of EcoRI and HpaII restriction enzymes. The se-
quences of the EcoRI preselective primer (EcoRI-00) and the HpaII
preselective primers (HpaII-00) were 5-AGACTGCGTACCAATTC-3
and 5-TCATGAGTCCTGCTCGG-3, respectively. Two microliters of
the digestion-ligation mix (diluted 1:3) were added to the pre-amplifi-
cation mix consisting of 1 PCR Buffer, 0.1 mM dNTP, 50 ng of
EcoRI-00 primer, 50 ng of HpaII-00 primer, and 1 unit of Taq poly-
merase (Roche Biochemicals). The PCR conditions were as follows:
72 °C for 2 min, 94 °C for 3 min, followed by 25 cycles as follows: 95 °C
for 30 s, 56 °C for 30 s, 72 °C for 1 min. A final extension was performed
at 72 °C for 4 min.
Selective Amplification—The sequence of the selective primers was
identical to the preselective primers but included the addition of a
number of nucleotides at the 3 terminus. The selective nucleotides of
the EcoRI-00 primer were as follows: EcoRI-01, AGT; EcoRI-02, ACA;
EcoRI-03, AGA; and EcoRI-04, ACC. The HpaII selective primers were:
HpaII-01, TCCA; HpaII-02, TAGC; HpaII-03, CGAA; HpaII-03A,
CGTT; HpaII-04, AATT; and HpaII-04A, AACC. Selective PCR was
conducted using 2 l of pre-amplification mix (diluted 1:10) in a 10-l
reaction volume containing 1 PCR Buffer, 0.1 mM dNTP, 50 ng of
EcoRI-00 primer, 50 ng of 33P-labeled HpaII-00 primer, and 1 unit of
Taq polymerase. The HpaII primer was end-labeled by incubating 50 ng
of primer with 50 Ci of [-33P]dATP, 10 units of polynucleotide kinase
and 5 l of 1 OPA buffer (Amersham Biosciences, Buckinghamshire,
UK). The reaction was incubated for 1 h at 37 °C, followed by heat
inactivation for 15 min at 65 °C. The PCR cycle employed was a stand-
ard amplified fragment length polymorphism touchdown protocol (25).
Polyacrylamide Gel Electrophoresis—The PCR samples were mixed
1:1 (v/v) with denaturating buffer (98% formamide, 10 mM EDTA, 0.1%
bromphenol blue, and 0.1% xylene cyanol) and separated on 6% poly-
acrylamide sequencing gel (Bio-Rad) for 3 h at 90 watts. Gels were dried
and exposed to x-ray film (BioMax, Eastman Kodak Co.) for 1–4 days at
80 °C. For each experiment, two or three independent MSAP reac-
tions, each corresponding to pooled samples from three or four mice,
were performed. If the results were reproducible, one sample was used
for further analysis. Quantitative analyses of band patterns were con-
ducted on central portions of gels, where resolution was maximal.
SssI Methyl-accepting Assay—The assay was performed as previ-
ously described (26), with the exception that Nonidet P-40 was replaced
with Triton and labeled DNA was blotted on a Nytran SuPerCharge
membrane (Schleicher & Schuell, Dassel, Germany).
Isolation and Sequencing of MSAP Bands—Bands were excised from
acrylamide gels, suspended in 30 l of 0.5 TE buffer, and incubated for
10 min at 65 °C. One microliter of the solution was used in a standard
PCR reaction with the appropriate primer combinations. The resulting
fragments were cloned in the pCR®II-TOPO® vector (Invitrogen, Paisley,
UK), and three independent clones were sequenced. Homology searches
were conducted using NIX software (www.hgmp.mrc.ac.uk).
The CpG ratio was calculated by dividing the number of observed CG
dinucleotides by their expected number, calculated with the formula
(number of cytosines)(number of guanines)/(total number of nucleotides).
Southern Blotting and Methylation-sensitive PCR Analysis of DMR—
Fifteen micrograms of genomic DNA were digested overnight with the
appropriate restriction enzyme, blotted, and probed with selected la-
beled MSAP fragments. Hybridization was conducted by using the
ULTRAhybTM system according to instructions from the manufacturer
(Ambion, Huntingdon, UK).
Selected fragments for which flanking sequences could be deduced
from data base matches were analyzed by methylation-sensitive PCR
(27). Two hundred nanograms of DNA was amplified with the following
fragment-specific primers. Fragment sz44 consisted of internal primer,
5-TAGCAGAGACCTAGAAGAGGG-3 (forward); and flanking primer,
5-TTCAAAAGTTGCCTCAAGTCC-3 (reverse), corresponding to
nucleotides 70314–70294 of sequence with accession no. AC103664.
Fragment M54 consisted of internal primer, 5-TGTGTTTTCCTCTCT-
TAGCCC-3 (forward); and flanking primer, 5-TTCTCAGCCATTCGG-
TATTCC-3 (reverse), corresponding to nucleotides 86183–86163 of
sequence with accession no. AC120437. Fragment M4 consisted of
internal primer, 5-AGTGCCTGTGATCCTTACCTG-3 (forward); and
flanking primer, 5-AAAGCTCAGAGTAGAAAAGGG-3 (reverse),
corresponding to nucleotides 194754–194774 of sequence with ac-
cession no. AC132863. Conditions were as follows: 94 °C for 1 min;
followed by 35 cycles at 94, 51, and 72 °C, each for 1 min; and a final
extension step at 72 °C for 10 min. Predicted PCR fragments were sz44,
399 bp; M54, 327 bp; and M4, 282 bp.
Expression Analysis by Reverse Transcription-PCR—Expression
analysis of leukocytic MSAP polymorphic fragments showing homology
to EST or genomic sequences (see “Results”) was conducted by using
fragment-specific nested primers. Gapdh RNA was amplified as an
internal control (Clontech, Palo Alto, CA). Primer identity and PCR
conditions are available upon request.
Southern Blotting Analysis of LINE-1 Elements—A 548-bp probe
spanning a conserved 5 region sequence in mouse LINE-1 elements
(28) was constructed by subjecting mouse tail genomic DNA to PCR
with the primers 5-ATCTTGGTTCGGGACCCGCCGAACTTAGG-3
(forward) and 5-GTTTACCTTTCGCCATCTGGTAATCTCTGG-3 (re-
verse). Conditions were as follows: 94 °C for 1 min; followed by 35 cycles
at 94, 60, and 72 °C, each for 1 min; and a final extension step at 72 °C
for 10 min. The probe was sequenced and used in Southern blotting as
indicated in the previous paragraph.
Cell Culture and Lipoprotein Isolation—Human THP-1 cells were
maintained in RPMI 1640 medium supplemented with fetal calf serum
(10%), glutamine (4 mM), penicillin (20 IU/ml), and streptomycin (20
g/ml). Cells were either used as monocytes or differentiated to macro-
phages by incubation with phorbol myristate acetate (50 ng/ml) for 4
days with change of medium every second day. For experiments, both
monocytes and macrophages were incubated for 24 h in serum-free
media with lipoprotein additions as indicated under “Results.” Lipopro-
teins were prepared by differential ultracentrifugation of fresh plasma
from healthy donors (29).
Quantification of Total 5-Methylcytosine by High Performance Cap-
illary Electrophoresis (HPCE)—Quantification of the degree of methyl-
ation was carried out as previously described (30, 31). Briefly, genomic
DNA (3–5 g) was obtained by standard procedures and DNA hydrol-
ysis was carried out with 1.25 l (200 units/ml) of nuclease P1 for 16 h
at 37 °C. Subsequently, alkaline phosphatase was added and mixtures
were incubated for an additional 2 h at 37 °C. Hydrolyzed samples were
injected under pressure (0.3 p.s.i.) for 3 s into an uncoated fused-silica
capillary in a CE system (P/ACTM MDQ, Beckman-Coulter). Quantifi-
cation of the relative methylation of each DNA sample was determined
as the percentage of 5-methylcytosine (mC) of total cytosines: mC peak
area  100/(C peak area  mC peak area). All samples were analyzed in
duplicate, and three analytical measurements were made per replicate.
Quantification of Whole Histone H4 Acetylation and Methylation of
Lysine 20 by HPCE—Quantification of acetylation and methylation at
lysine 20 of histone H4 was done by a modification of the method
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previously described (32). Individual histone fractions were obtained
from cell nuclei (33), and further purified by reversed-phase HPLC (34).
The non-, mono-, di-, tri-, and tetra-acetylated forms of histones H3 and
H4 and trimethylated H4 at lysine 20 were resolved by HPCE, using an
uncoated fused-silica capillary (Beckman-CoulterTM) (60.2 cm  75 mm,
effective length 50 cm) in a CE system (P/ACETM MDQ, Beckman-
CoulterTM). The running buffer was 100 mM phosphate buffer, pH 2.0,
containing 0.02% (w/v) HPM-cellulose. Running conditions were 25 °C
and operating voltages of 12 kV. On-column absorbance was monitored
at 214 nm. Before each run, the capillary system was conditioned by
washing with 0.1 M NaOH for 3 min, and with 0.5 M H2SO4 for 2 min,
and equilibrated with running buffer for 3 min. Buffers and washing
solutions were prepared with Milli-Q water and filtered throughout
0.45-m filters. Samples were injected under pressure (0.3 p.s.i.) for 3 s.
All samples were analyzed in duplicate, and three analytical measure-
ments were made per replicate.
Statistics—Comparisons were made by using nonparametric tests in
the StatView (Abacus Concept, Berkeley, CA) or Statistica (StatSoft,
Tulsa, OK) program for Macintosh. The counts of DNA methylation
polymorphic bands were compared in samples paired by selective
primer, using the Wilcoxon paired test. In all other cases, tests are
specified under “Results.”
RESULTS
Changes in PBMC and Aortic DNA Methylation Profiles Pre-
cede Fibrocellular Vascular Lesions in Apoe/ Mice—To study
DNA methylation patterns during the progression of athero-
sclerosis, 4-week-old and 6-month-old APOE-null (Apoe/)
were used. Mice were fed normal rodent diet, to exclude any
confounding contribution of dietary factors potentially affecting
DNA methylation (35). At the age of 4 weeks, mutant mice were
hypercholesterolemic but lacked any detectable fatty streak or
fibrocellular lesions at the ascending aorta or at the aortic arch
(Fig. 1, A and B). By contrast, lesions consisting of a fibrocel-
lular intima and a lipid-rich core were detectable in the same
portion of the aortic vessel in 6-month-old Apoe/ mice as
previously reported (Fig. 1, C and D) (20). Plasma total choles-
terol was markedly elevated in Apoe/ mice of both age
groups, relative to WT controls (Fig. 1, compare A and C with
B and D) (20).
To screen PBMC for DNA methylation polymorphisms
(DMPs) between Apoe/ mice and matched controls, we
exploited the MSAP fingerprinting technique. This technique
is a modification of amplified fragment length polymorphism,
a procedure that is based on random amplification of restric-
tion fragments typically generated by digestion of genomic
DNA with the EcoRI and MseI restriction enzymes (25). In
MSAP, MseI is replaced by the methylation-sensitive enzyme
HpaII, blocked by methylation at either cytosine residue in
the recognition site 5-CCGG-3 (24). Following digestion of
genomic DNA, adaptors are attached to restriction sites that
have been successfully digested. It follows that the products
of the MSAP ligation reaction consist of DNA fragments that
are flanked by hypomethylated HpaII and EcoRI sites. There-
after, two consecutive PCR reactions, a preamplification and
a selective amplification, are performed to enrich a subpopu-
lation of the restriction fragments. The primers employed are
complementary to the core sequence of adaptors and recog-
nition sites of the restriction enzymes, and the number of
nucleotides added to their 3 terminus determines their se-
lectivity. Typically the number of selective nucleotides is
increased in the selective amplification, where one of the two
primers is radioactively labeled. This enables the visualiza-
tion of a subset of restriction fragments by autoradiography
following acrylamide gel electrophoresis.
PBMC DNA was screened by MSAP, using 23 different com-
binations of selective primers, corresponding to a total of
1,600 bands/genotype group. Parallel MSAP analyses were
conducted with MspI, an isoschizomer of HpaII that is only
sensitive to methylation at the external cytosine (methylation
at CNG trinucleotide) on one or both strands (methylation on
one strand only is referred to as hemimethylation). It follows
that an HpaII polymorphism between WT and Apoe/ sam-
ples can be attributed to differential CG methylation, if the
corresponding MspI profile is monomorphic, i.e. either present
or absent in both genotypes (Fig. 2A). In the latter case, the
HpaII site is hemimethylated at the external cytosine in both
genotypes (lower bands in Fig. 2A) (36). Alternatively, absence
of MspI fragments may result from inefficient amplification of
the more complex MspI amplicons, relative to HpaII products.
Nonetheless, the stability of MspI profiles observed throughout
our study argues against this hypothesis. A polymorphism
detected with both HpaII and MspI digestion is indicative of
CNG methylation or mutation at the targeted Apoe alleles or
elsewhere (Fig. 2B).
The analysis revealed that polymorphisms were present at
both 4 weeks and 6 months of age (Fig. 3). Although DMPs may
contain internal hypermethylated HpaII or EcoRI sites, previ-
ous analyses revealed that the vast majority of MSAP products
represent HpaII-EcoRI fragments that lack any internal HpaII
or EcoRI site (37). Accordingly, in the present study, only 5% of
the sequenced MSAP fragments (see below) contained an in-
ternal HpaII site and none contained any EcoRI site. This
implies that hypermethylation of internal fragment sites af-
fects only marginally, if at all, the assessment of genome meth-
ylation status by MSAP band scoring. Two hundred and eight
of the 206 polymorphisms observed at 4 weeks and 6 months
(counting polymorphisms that are common to both ages only
once) represented changes in CG methylation, e.g. genuine
DMPs (Fig. 3, A and B), whereas only one band represented a
difference in CNG methylation or a mutation (Fig. 3C).
The total number of DMPs in 4-week-old PBMC was 48, or
3.2% of total bands. A similar analysis conducted on 6-month-old
mice revealed that the total number of DMPs was increased by
3.8-fold to 185, or 11% of total bands, compared with the younger
age group (p  0.002). DMPs that were present in both age
groups represented a substantial part of all DMPs at 4 weeks (27
of 48, or 56%), but were a minority at 6 months (15%).
An identical MSAP analysis was conducted on aortic DNA,
using 14 selective primer combinations, producing a total of
1,000 bands. Aortic DMPs showed a markedly different dis-
FIG. 1. Atherosclerotic lesions in Apoe/ mice at different
ages. Panels are cryosections of the ascending aorta of Apoe/ (A and
C) and WT (B and D) mice at the age of 4 weeks (A and B) and 6 months
(C and D). The arrow in C indicates a fibrocellular lesion. Numbers in
each photograph represent plasma total cholesterol levels (mg/ml).
Staining, Oil Red O and hematoxylin. Original magnification, 20. Bar,
0.2 mm.
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tribution, in comparison with PBMC DNA. The total number of
DMPs showed little or no increase with age, being 76 and 83 (or
7.6% and 8.3% of total bands) at 4 weeks and 6 months, respec-
tively. Furthermore, approximately one third of DMPs were
conserved in both age groups. The comparison of PBMC and
aortic MSAP analyses revealed that few DMPs were common to
the PBMC and the aorta (2 of 137 total aortic DMPs at 4 weeks
and 6 months, counting polymorphisms that are common to
both ages only once).
Further MSAP analysis was conducted on pericardial fat and
liver of 6-month-old mice by using six primer combinations. In
these tissues, the frequency of DMPs was severalfold lower
than in matched PBMC and aorta (i.e. 0.5–1% of total bands;
p  0.03 in all comparisons). This indicates that the bulk of
DMPs observed in Apoe/ mice from the age of 4 weeks on
represented genotype-related and tissue-specific, rather than
reflecting inter- or intra-individual epigenetic variations that
are unrelated to the Apoe genotype (see, for example, Ref. 38).
Hypo- and Hypermethylation in Apoe/ Mice—A DMP that
is characterized by a band specifically present in Apoe/
mutant (MDMP) or WT (WDMP) mice, implies hypo- or hyper-
methylation at the flanking HpaII site, respectively, in
Apoe/ mice compared with WT. Previous comparisons of
parallel results obtained with MSAP and direct quantitation of
mC by HPCE, established that the total number of bands pro-
duced by MSAP accurately reflects the genome-wide methyla-
tion status of a particular DNA sample (37). Therefore, the
relative proportion of MDMPs and WDMPs allows the estima-
tion of the level of hypo- or hypermethylation of Apoe/ DNA.
Both MDMPs and WDMPs were observed in all samples
analyzed, albeit at a different relative extent in different tis-
sues and age groups, indicating that hypo- and hypermethyla-
tion occurred simultaneously in Apoe/ DNA (Table I). In
4-week-old mice, the relative proportion of MDMPs and
WDMPs was similar in PBMC, whereas a significant excess
of MDMPs was observed in the aorta (Table I). By contrast,
MDMPs were significantly more frequent than WDMPs in both
PBMC and aorta of 6-month-old mice (Table I). The net extent
of Apoe/ DNA hypomethylation, was measured by dividing
the difference between the number of MDMPs and WDMPs by
the total number of bands. DNA hypomethylation did not ex-
ceed 4% and was higher in the aorta compared with PBMC
(Table I).
To corroborate the result of the MSAP analysis, we assessed
the relative methylation status of Apoe/ and control DNA, by
the SssI methyl-accepting assay. SssI methyltransferase is a
bacterial enzyme that transfers methyl groups to cytosine res-
idues in a CG dinucleotide context, using SAM as a methyl
group donor. If labeled SAM is used in the reaction, the incor-
poration of radioactivity in DNA is proportional to the extent of
initial hypomethylation. In accordance with the data obtained
by MSAP, 4-week-old Apoe/ aortic, but not PBMC DNA,
showed a significant decline in global methylation, whereas
hypomethylation was detected in both samples of older
Apoe/ mice (Fig. 4, A and B). By contrast, no significant
difference in liver or skeletal muscle DNA methylation was
detected between Apoe/ and control mice (Fig. 4, A and B).
Furthermore, the SssI methyl-accepting assay allows to esti-
mate the number of demethylated CG sites in Apoe/ mice
relative to controls, and therefore yields an estimation of the
relative extent of global DNA hypomethylation. Again in ac-
cordance with the results of MSAP, DNA hypomethylation was
more pronounced in the aorta, compared with PBMC (0.40 
105 (n  5) and 0.64  105 (n  12) demethylated CG sites/
haploid genome, respectively) at 6 months, and was lower than
either sample in aortas of 4-week-old mice (0.25  105 (n  12);
compare with values in Table I).
Characterization of Variably Methylated Sequences—To
characterize the PBMC DMPs, MSAP fragments were excised
from acrylamide gels, reamplified by PCR, cloned, and sub-
jected to sequencing in triplicate. The following DMPs were
chosen: all the age-independent DMPs, all 4-week-specific
DMPs, and 29 randomly chosen 6-month-specific DMPs. Sixty
FIG. 3. The majority of polymorphisms detected by MSAP in
PBMC represent changes in CG methylation. Representative exam-
ples of MSAP analysis of PBMC DNA of Apoe/ mutant and WT mice (m
and WT, respectively) digested with the indicated enzymes. The frequency
and cause of polymorphisms are indicated on the right. Figures represent
the number of bands of a given polymorphism/number of total PBMC
polymorphisms (i.e. at 4 weeks and 6 months, counting polymorphisms
common to both ages only once). A, DMP characterized by the presence of
the MspI product in both genotypes. B, DMP characterized by the absence
of any MspI product from both genotypes. C, polymorphism characterized
by variability in both HpaII and MspI products.
FIG. 2. Outcome and interpretation of MSAP analysis. Figure shows a schematic representation of banding patterns obtained by digestion
of Apoe/ or WT DNA with HpaII and EcoRI or MspI and EcoRI. Solid and dashed lines indicate present and absent bands, respectively. For
clarity, only polymorphisms characterized by bands specifically present in WT DNA are shown. Flanking EcoRI (E) and HpaII/MspI (CCGG) sites
are shown. The methylation status of the HpaII/MspI site is also indicated (hmC, hemimethylated cytosine, i.e. methylated on one strand only).
Question marks indicate possible presence of a mutation.
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fragments were successfully sequenced, ranging from 60 to 543
bp in size. Twenty-four PBMC DMPs matched data base se-
quences, all of which were murine (Table II). The majority of
DMPs exhibited identity to relatively uncharacterized mouse
genomic sequences. The remaining DMPs showed homology
with repeated elements, as well as with ESTs (Table II). A
reverse transcription-PCR-based expression analysis was con-
ducted in 6-month-old mice for selected clones displaying ho-
mology to ESTs or genomic sequences (M1, M42, M45, M46,
and M49; Table II). Two DMPs, one of which homologous to an
EST (M45 and M49) showed specific expression in Apoe/
PBMC (data not shown), in accordance with their hypometh-
ylated status in that group.
Based on the above data, we could not estimate the relative
contribution of genic sequences and interspersed repeated ele-
ments to the observed changes of DNA methylation patterns in
Apoe/ mice. To clarify this issue, we analyzed the methyla-
tion status of the highly repeated LINE-1 retrotransposon ele-
ments in aortic DNA by Southern blotting. In tumors, demethyl-
ation of LINE-1 sequences, detected by the appearance of
bands in the 1–4-kb range after digestion with HpaII, is a
landmark of global genomic hypomethylation (39). However, no
obvious hypomethylation of LINE-1 sequences was detected in
the aortic tissue of 6-month-old Apoe/ mice (data not shown).
Southern Blotting and HpaII-sensitive PCR Analysis of
DMPs—DMP profiles and their tissue specificity were verified
by Southern blotting and HpaII-sensitive PCR of seven ran-
domly chosen PBMC DMPs. Representative results of four
DMPs are shown in Fig. 5. The WDMP M27 is a 304-bp MSAP
fragment that was hypermethylated in both 4-week-old and
6-month-old Apoe/ mice. Accordingly, Southern blotting
analysis revealed that the M27 probe hybridized to a band of
approximately the expected size in WT PBMC DNA digested
with HpaII and EcoRI, and in all samples digested with MspI
and EcoRI (Fig. 5A, arrow), whereas it hybridized to higher size
fragments in Apoe/ DNA from both age groups. By contrast,
hybridization of M27 to liver DNA-digested HpaII and EcoRI
did not reveal any polymorphism (Fig. 5A). In HpaII-sensitive
PCR, genomic DNA digested with HpaII was amplified with a
primer internal to the DMP fragment, and an external primer,
deduced by data base match sequences. Because primers were
placed at opposite sides of the DMP-flanking HpaII site, a
product could be obtained only if the corresponding HpaII site
was methylated. Apoe/ tail DNA was used as control to
assess the tissue specificity of DNA methylation patterns. The
analysis showed that the amplification of MDMPs M4 and M54
was reduced in 4-week-old Apoe/ PBMC, relative to matched
WT PBMC or tail DNA, in accordance with their hypomethyl-
ated status in Apoe/ PBMC (Fig. 5B). The opposite pattern
was produced by the WDMP sz44, as expected (Fig. 5B). Am-
plification following MspI digestion failed to yield any product
in all cases (data not shown).
Effects of Lipoproteins on DNA Methylation and Histone H4
Modifications in THP-1 Cells—The occurrence of both local
hyper- and hypomethylation of Apoe/ DNA at the initial
stages of atherosclerosis suggests that at least a subset of the
observed changes in DNA methylation profiles are active cel-
lular responses to proatherogenic factors. The latter may in-
TABLE I
Hypo- and hypermethylation in Apoe/ mice
p values refer to differences in DMP counts ( 2 test). NS, not signif-
icant (p  0.05). NC, not calculated.
Type of DMP
PBMC Aorta
4 weeks 6 months 4 weeks 6 months
MDMPs 26 111 45 62
WDMPs 22 74 31 21
p NS 0.04 0.02 0.003
Extent of net DNA
hypomethylation (%)
NC 2.5 1.4 4.1
FIG. 4. Genome hypomethylation is tissue-specific in Apoe/
mice. Figure is a SssI methyl-accepting assay showing the extent of
incorporation of tritiated methyl groups into DNA from 4-week-old (A)
and 6-month-old (B) mice. Each data point represents an individual
mouse. The analyzed tissue and sample size are indicated at the bottom
of the figure. For each tissue, data points relative to Apoe/ and WT
DNA are on the left and right side, respectively. Significantly different
samples are indicated by asterisks.
TABLE II
PBMC DMP sequences with significant matches in data bases
Lowest E value of data base matches was 1058. SINE, short inter-
spersed nuclear element; LTR, long terminal repeat; ERVK, endoge-
nous retrovirus K.
Clone Size Accession no. Type of sequence
bp
M1 152 BM875787 EST
M4 253 AC132863 SINE
M7 167 AC115816 Genomic
M12 131 AC024607 Genomic
M26 301 LTR/ERVK
M27 303 AC102506 Genomic
M30 216 BX322546 Genomic
M42 157 AL807763 Genomic
M45 107 AC135019 Genomic
M46 285 AC122350 Genomic
M49 141 BY249272 EST
M50 61 AC140236 Genomic
M52 223 AC103622 Genomic
M54 383 AC120437 Genomic
M55 226 AC101290 Genomic
M58 236 LINE
M62 295 LTR
sz44 317 AC103664 Genomic
sz47 181 LINE
sz23 89 AC129780 Genomic
szc7 543 SINE
szc9 458 AC101947 Genomic
szc13 340 AC115970 Genomic
szc14 343 LINE
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clude deranged levels of lipoproteins, because hyperlipidemia
plays a pivotal role in the initiation of atherosclerosis and
precedes the appearance of vascular lesions in Apoe/ mice.
To verify this hypothesis, we stimulated the human monocytic
THP-1 cells with a mixture of VLDL, LDL, and HDL, and
explored the effects on global genomic DNA methylation, by
measuring the relative content of mC. THP-1 cells can differ-
entiate into macrophage-like cells by treatment with phorbol
esters, and are therefore a model for studying the role of in-
flammatory cells in atherosclerosis (21). Two lipoprotein mix-
tures were used. The first contains lipoproteins at relative
plasma proportions consistently observed during our previous
studies of Apoe/ mice (68.8 g/ml VLDL, 32.1 g/ml LDL,
91.1 g/ml HDL, referred to as HL mixture). The second mix-
ture reproduces relative lipoprotein proportion of WT mice (4.3
g/ml VLDL, 2.9 g/ml LDL, 116 g/ml HDL, referred to as WL
mixture). The HL and WL mixture differ for the ratio between
the composite amount of the atherogenic VLDL and LDL par-
ticles, and the amount of the antiatherogenic HDL (1.11 and
0.06, respectively), corresponding to an 18-fold higher ratio in
the HL, relative to the WL mixture. In absolute terms, the HL
and WL mixtures contained one tenth of the lipoprotein con-
centrations present in their in vivo counterpart, or a maximum
cumulative concentration of 100.9 g/ml VLDL  LDL. These
concentrations were chosen as too high lipoprotein levels are
cytotoxic, and incubation with up to 150 g/ml VLDL for 24 h
do not induce cell death in THP-1 cells (data not shown).
Stimulation of differentiated THP-1 cells with HL mixture
for 24 h induced a significant increase in DNA methylation,
compared with matched controls or cells stimulated with the
WL mixture (p  0.0003, Scheffe test), whereas the latter
treatment had no significant effect (Fig. 6A). By contrast, no
statistically significant effect of lipoproteins was observed in
undifferentiated THP-1 cells (Fig. 6A). To further understand
the effects of lipoproteins on chromatin structure, we analyzed
two post-translational modifications of the histone H4, namely
acetylation and methylation at lysine 20 (Lys-20). H4 acetyla-
tion is generally associated with a transcriptionally active
state, whereas deacetylation is associated with gene silencing
and heterochromatin formation (40). Furthermore, trimethyla-
tion of Lys-20 of H4 has been associated with silent chromatin
and aging (41, 42). Increasing doses of VLDL and LDL had no
statistically significant effect on either histone modification
(Kruskal-Wallis analysis of variance), whereas differentiated
cells showed a significant decrease in histone H4 acetylation
and an increase in H4 tri-/dimethyl-Lys-20 ratio, both land-
marks of heterochromatin formation (p  0.0003 for both,
Scheffe test, Fig. 6, B and C). Overall, the triple global pattern
of hypermethylation of DNA and H4, and loss of histone acety-
lation observed in the cells treated with atherogenic lipopro-
teins, suggest that gene silencing and the formation of hetero-
chromatin are early molecular “hits” that precede, and
probably contribute to, the histopathological traits associated
with atherosclerosis.
FIG. 5. Analysis of DMPs by Southern blotting and HpaII-sen-
sitive PCR. A, Southern blot analysis conducted with a probe corre-
sponding to PBMC DMP M27. The arrow indicates the position of
genomic hybridizing fragment corresponding to the MSAP DMP. Size of
DNA markers are shown on the right (kb). B, HpaII-sensitive PCR
analysis of the indicated PBMC DMPs at 4 weeks. Expected sizes of
PCR products were 282, 327 and 399 bp, respectively. Size of DNA
markers is shown on the right of gel (bp). Abbreviations are as in the
legend of Fig. 3.
FIG. 6. Effects of lipoproteins on DNA methylation and histone
H4 post-translational modifications in THP-1 cells. Panels show
box and Whisker plots of the effects of the WL and HL lipoprotein
mixtures on mC content (A), levels of acetylated histone H4 (B), and
ratio between tri-methylated and di-methylated histone H4 lysine 20
(C) in undifferentiated and differentiated THP-1 cells. Control, incuba-
tion without lipoproteins. HL and WL, high and low VLDLLDL lipid
mixtures, respectively, as described under “Results.” The average of
triplicate measurements, with S.D. and S.E., are shown for each sam-
ple. Asterisks represent the significance levels compared with matched
controls (Scheffe test).
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DISCUSSION
The present work expands the current knowledge on the role
of DNA methylation in atherosclerosis, by showing that DMPs
are present prior to the appearance of vascular lesions in
Apoe/ mice. Noticeably, DMPs were significantly more fre-
quent in organs and cell types involved in the initiation and
progression of atherosclerosis, e.g. the aorta, circulating in-
flammatory cells, and/or immune cells (43, 44), in comparison
with the control tissues examined (liver, pericardial fat, skele-
tal muscle). Furthermore, few DMPs were common to PBMC
and the aorta, mirroring the functional differences between the
two tissues. Taken together, the observed mosaicism and tissue
specificity of DMPs suggest that these epigenetic marks are
specifically associated with predisposition to and progression of
atherosclerosis, rather than originating from genetic or sto-
chastic epigenetic variability. An additional factor known to
affect DNA methylation patterns is transgene integration, im-
plying that a similar effect may be exerted by the insertion of
exogenous sequences into targeted Apoe alleles (45). Neverthe-
less, the mosaic nature of the observed DMP strongly argues
against such a mechanism.
In agreement with previous studies, we observe a modest,
but significant global hypomethylation of genomic DNA in aor-
tas and PBMC of Apoe/ mice afflicted by fibrocellular lesions
(18, 19). The extent of aortic DNA hypomethylation observed in
our study was lower in comparison with the corresponding
value obtained by Hiltunen and colleagues (18) in Apoe/
mice, humans, and rabbits. These discrepancies have several
possible explanations. First, Hiltunen and colleagues assessed
the effects of dietary lipids, regardless of the consequences of
atherosclerosis per se in Apoe/ mice (e.g. in comparison with
matched WT mice). Similarly, the work conducted by the same
group in rabbits analyzed the epigenetic effects of dietary lipids
and cell proliferation following arterial denudation, rather
than genuine atherosclerosis. Furthermore, the measurement
of DNA methylation in human atherosclerotic lesions is poten-
tially affected by inter- and even intra-individual epigenetic
variability, particularly in samples that are forcibly of rela-
tively limited size (18, 38). In accordance with the modest net
DNA hypomethylation estimated by MSAP, methylation of
LINE-1 sequences was not detectably changed in Apoe/ aor-
tic DNA compared with controls. Taken together, these obser-
vations suggest that the mechanism of genome hypomethyla-
tion differs in atherosclerosis, cancer, and aging, and that
similarities between the epigenetics of these pathophysiologi-
cal situations must be drawn with caution. Our results suggest
that atherosclerosis is associated with a significant rearrange-
ment of DNA methylation patterns, including both hyper- and
hypomethylation, in the PBMC and the aorta. The samples
analyzed in this study represent heterogeneous cell popula-
tions; therefore, more extreme changes in DNA methylation,
perhaps including hypomethylation to levels observed in cancer
and aging, cannot be excluded to occur in selected cell types.
The results of sequencing and expression analysis suggest that
at least some of the observed DMPs represent genic sequences.
Correlative studies suggest that DNA hypomethylation may
be a passive phenomenon because of the depletion of cellular
SAM in hyperhomocysteinemia (19, 46, 47). However, hyper-
homocysteinemia is not a trait of Apoe/ mice, implying that
the process is not merely a passive consequence of the depletion
of cellular SAM (48). Rather, our results suggest that DMPs are
the compound result of active and passive mechanisms. The
finding that lipoproteins induce DNA hypermethylation in cul-
tured cells suggests that changes in DNA methylation are
among the earliest cellular changes in atherosclerosis. Further-
more, these observations demonstrate for the first time a direct
link between a pro-atherogenic factor (the hyperlipidemic li-
poprotein profile) and changes in DNA methylation. Our re-
sults are consistent with the observation that the atheropro-
tective HDL causes chromatin activation in cell culture (49). As
the disease progresses, and the involvement of SMC becomes
more significant (43), hyperproliferation of the latter cell type
in the fibromuscular lesion may then tip the balance of global
genome methylation status toward hypomethylation, as previ-
ously shown (18). The mechanisms by which lipoproteins can
affect DNA methylation patterns are currently not understood.
APOA-I, a constituent of HDL, is physically associated with
active chromatin and binds to a CG-rich oligonucleotide in
vitro, suggesting a role for lipoprotein constituents in chroma-
tin binding and remodeling (50, 51). Further studies are nec-
essary to elucidate the functional consequences of these inter-
actions in atherogenesis.
Incidentally, we show that deacetylation and increased tri-
methylation of histone H4 lysine 20 occur in differentiated,
unstimulated THP-1 cells in the absence of a significant DNA
hypermethylation. Further investigations are needed to inter-
pret this result in the light of the current models of heterochro-
matin formation (52, 53).
In conclusion, we report that specific changes in DNA meth-
ylation occur during the early phases of atherosclerosis in a
mouse model. Furthermore, by showing that DMPs are present
in accessible cell types such as PBMC at early stages of ather-
osclerosis, our work points to epigenetic marks as potential
novel tools for prevention and therapy.
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